Glenmark Pharmaceuticals (www.glenmarkpharma.com) is a global innovative pharmaceutical company with operations in more than 50 countries. Glenmark has a diverse pipeline with several compounds in various stages of clinical development, primarily focused in the areas of oncology, respiratory disease and dermatology.
Glenmark’s biologics research operations in Switzerland focuses on the discovery and development of new biological entities from inception through preclinical and clinical studies. With a world-class, GMP-certified manufacturing line, our Swiss site located in the canton of Neuchâtel is well-positioned to fully serve the company’s growth in biologics research and development. The facility provides Glenmark with a complete suite of end-to-end, in-house capabilities necessary for early production of investigational biologics medicines, including cell line development, bioassay development and antibody engineering, as well as upstream and downstream development.
Investing in groundbreaking technologies, platforms and facilities ensures we will continue to drive innovation within our pipeline. With this in mind, Glenmark will open a new discovery centre at Biopôle in Lausanne-Epalinges in October 2018. This site will enhance Glenmark’s capabilities in translational research by joining the most vibrant ecosystems for life sciences innovation in Europe. Our offices at Biopôle in Lausanne will focus primarily on the areas of immunology, antibody engineering, and translational medicine.
Glenmark is a rapidly growing company with many exciting and challenging career opportunities. We continue to recruit talented professionals who would like to contribute to our success and who share our values of respect, knowledge and achievement.